DFine closes $36 million in funding

With the help of six venture capital investors and several unnamed private investors, San Jose, CA-based DFine has closed a $36.2 million round of funding.

"This funding will enable us to put additional resources in the field to support the growing demand for our StabiliT Vertebral Augmentation System, and to accelerate the commercialization of several promising products in our pipeline," says DFine CEO Kevin Mosher in a statement. DFine's new investors, OrbiMed and Split Rock partners, join four other venture capital firms in spearheading this round of equity financing. In connection with the financing, Josh Baltzell of Split Rock and Jonathan Silverstein of OrbiMed will join DFine's board of directors.

DFine creates treatment devices for vertebral pathologies, including StabiliT and Radio Frequency Kyphoplasty, which improve patients' quality of life and reduce pain.

- read the DFine release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.